Mirion Technologies' 15min chart signals RSI overbought, KDJ death cross.

Mirion Technologies' 15-minute chart has triggered an overbought RSI reading and a death cross on the KDJ indicator as of August 13, 2025 at 09:45. This suggests that the stock price has risen too rapidly and is now exceeding its fundamental support levels. The momentum of the stock price is shifting towards the downside, and there is potential for further price decreases.

Mirion Technologies Inc. (MIR) experienced a significant upward movement in its stock price, driven by robust Q2 2025 earnings and strong fundamentals. However, recent technical indicators suggest a potential shift in momentum towards the downside. On August 13, 2025, at 09:45, Mirion Technologies' 15-minute chart triggered an overbought RSI reading and a KDJ death cross, signaling a possible downward trend.

The Relative Strength Index (RSI) reading of over 70 indicates that the stock price has risen too quickly, potentially outpacing fundamental support. The KDJ death cross, where the K line crosses below the D line, signals a bearish trend reversal. These technical indicators suggest that Mirion Pharmaceuticals' stock price may be overvalued and could experience further decline.

Citizens JMP analyst Jonathan Wolleben raised the price target for Mirion Technologies to $81 from $79 and maintained an Outperform rating, citing strong Q2 sales and the continued success of its products [1]. Despite this positive outlook, the technical indicators suggest a potential downward trend that investors should be aware of.

Mirion Technologies' robust performance in Q2 2025 underscores its strategic focus on commercial execution, scientific innovation, and financial discipline. However, the recent technical indicators indicate a need for caution among investors. As the company continues to develop life-changing medicines for patients with rare diseases, the potential for further downward pressure on the stock price should not be overlooked.

Investors looking to make a profit from stocks that are currently on the move may find our "Recent Price Strength" screen useful. This predefined screen helps spot stocks that are on an uptrend backed by strength in their fundamentals, and trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness [2].

Mirion Technologies, Inc. (MIR) is one of the suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for "trend" investors. A solid price increase over a period of 12 weeks reflects investors' continued willingness to pay more for the potential upside in a stock. MIR is quite a good fit in this regard, gaining 22% over this period. However, it's not enough to look at the price change for around three months, as it doesn't reflect any trend reversal that might have happened in a shorter time frame. It's important for a potential winner to maintain the price trend. A price increase of 2.9% over the past four weeks ensures that the trend is still in place for the stock of this company. Moreover, MIR is currently trading at 87% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.

Looking at the fundamentals, the stock currently carries a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises — the key factors that impact a stock's near-term price movements [2].

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988.

Another factor that confirms the company's fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock's near-term price performance.

So, the price trend in MIR may not reverse anytime soon.

References:
[1] https://www.investing.com/news/transcripts/earnings-call-transcript-mirum-pharmaceuticals-sees-revenue-boost-in-q2-2025-93CH-4175140
[2] https://www.citizensjmp.com/analyst-reports/mirion-technologies-inc